Dapagliflozin (BMS-512148; 達(dá)格列凈) CAS: 461432-26-8

規(guī)格	庫存	目錄價	會員專享價	數(shù)量
100 mg	In-stock	￥566.00	登錄后可見	- +
250 mg	In-stock	￥788.00	登錄后可見	- +
500 mg	In-stock	￥1488.00	登錄后可見	- +

規(guī)格

庫存

目錄價

會員專享價

數(shù)量

100 mg

In-stock

￥566.00

登錄后可見

- +

250 mg

In-stock

￥788.00

登錄后可見

- +

500 mg

In-stock

￥1488.00

登錄后可見

- +

基本信息

英文名稱	Dapagliflozin (BMS-512148; 達(dá)格列凈)
中文名稱	(2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基芐基)苯基)-6-(羥甲基)四氫-2H-吡喃-3,4,5-三醇
CAS號	461432-26-8
分子式	C21H25ClO6
分子量	408.87
MDL	MFCD13182359
外觀	White to off-white powder
儲存條件	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

產(chǎn)品詳情

Dapagliflozin (formerly known as BMS-512148; trade names Farxiga in the US and Forxiga in the EU) is a potent and selective hSGLT2 (sodium-glucose transport proteins) inhibitor with anti-diabetic activity. It inhibits hSGLT2 with an EC50 of 1.1 nM, and exhibits1200-fold selectivity over hSGLT1. Dapagliflozin inhibits subtype 2 of the sodium-glucose transport proteins (SGLT2) which are responsible for at least 90% of the glucose reabsorption in the kidney. Urine is the means by which blood glucose is expelled when this transporter mechanism is blocked.

相關(guān)文獻(xiàn)

抱歉，暫時沒有相關(guān)文獻(xiàn)

相關(guān)產(chǎn)品

抱歉，暫時沒有相關(guān)產(chǎn)品

瀏覽記錄

CL1127

(2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基芐基)苯基)-6-(羥甲基)四氫-2H-吡喃-3,4,5-三醇

461432-26-8 98+% In-stock

￥566.00 100 mg

久久久无码视频,影音先锋女人av噜噜色,久久久久无码国产精品Sm高潮,人人色综合

(2S,3R,4R,5S,6R)-2-(4-氯-3-(4-乙氧基芐基)苯基)-6-(羥甲基)四氫-2H-吡喃-3,4,5-三醇

Dapagliflozin (BMS-512148; 達(dá)格列凈)

化學(xué)品安全說明書(MSDS)

質(zhì)檢證書(COA)